Saturday 17 October 2026 Export ONC’s income statement to Excel — free account

BeOne Medicines Ltd. - Sponsored ADR

BeOne Medicines Ltd. - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $5.3 billion, up 40.2% from fiscal 2024. In the quarter to June 2026, revenue grew 29.6%, EPS grew 143.7%, free cash flow grew 117.9% and total debt rose 503.8%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.

369.06 5.02 −1.34%

Follow ONC

Alert me

Market cap: $39.0B
P/E: 62.6×
Fwd P/E: 40.2×
Dividend yield: —
F-score: 7/9
Altman Z: 5.25
Beneish M: −2.73
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 380.09

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	4	2	1	1	1	1	5	19	8	4	4	1

Insider Ownership 7.04%

Capital & Financial Ratios $m

Market Cap 39,010.00

Revenue 6,128.96

Net Income 655.71

Free Cash Flow 1,330.19

Net Debt (4,215.88)

Current Ratio 3.41

Debt/Equity 0.17

P/E ratio 62.55

Fwd P/E 40.20

P/S ratio 6.72

P/B ratio 7.96

Past 5Y EPS Growth —

This Y EPS Growth 176.61%

Next Y EPS Growth 37.50%

Next Y revenue growth 26.73%

Next 5Y EPS Growth 73.21%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 16.20%

10-year low 10-year high

P/B against its own 10 years 80.78%

10-year low 10-year high

EV/Sales against its own 10 years 16.94%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	3,172	2,627	4,548	5,098
Receivables	358	676	865	1,056
Inventory	416	495	608	733
Other	—	—	—	—
	4,203	3,992	6,234	7,216

	2023	2024	2025	Q'26
Payables	315	405	479	470
ST’ Debt	—	—	—	—
Other	68	111	121	95
	1,810	2,215	1,829	2,119

Compound Annual Growth %

	10y	5y	3y
Sales	89.78%	76.85%	55.69%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	50.26%	2.42%	(0.17%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	1,513	1,705	—	—	—
’25	1,117	1,315	1,412	1,498	5,343
’24	752	929	1,002	1,128	3,810
’23	448	595	781	634	2,459
’22	307	342	388	380	1,416
’21	606	150	206	214	1,176
’20	52	66	91	100	309

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	201	463	—	—	—
’25	44	264	403	417	1,128
’24	(309)	(96)	188	75	(141)
’23	(564)	(294)	(78)	(222)	(1,157)
’22	(237)	(380)	(562)	(318)	(1,497)
’21	125	(420)	(496)	(508)	(1,299)
’20	(342)	(263)	(346)	(332)	(1,283)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	161	435	—	—	—
’25	(12)	200	354	380	922
’24	(470)	(206)	55	(17)	(638)
’23	(689)	(415)	(245)	(389)	(1,739)
’22	(282)	(430)	(671)	(440)	(1,822)
’21	83	(459)	(563)	(666)	(1,605)
’20	(363)	(296)	(375)	(367)	(1,401)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	1.96	2.05	—	—	—
’25	0.01	0.84	1.09	0.58	2.53
’24	(2.41)	(1.15)	(1.15)	(1.43)	(6.12)
’23	(3.34)	(3.64)	2.01	(3.53)	(8.45)
’22	(4.24)	(5.56)	(5.39)	(4.29)	(19.43)
’21	0.69	(5.23)	(4.46)	(6.16)	(15.23)
’20	(4.70)	(4.31)	(4.81)	(5.20)	(19.13)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	22.51	29.58	95.34	108.00	118.55	222.21	118.18	156.56	126.97	172.67	Analyst estimates 2026–2028 Powerpack
	High	37.89	118.95	220.10	210.35	322.98	426.56	275.72	280.62	248.16	385.22
People
People	Employees	322	900	2,070	3,500	5,300	8,200	9,200	10,600	11,000	12,000
	Revenue/emp, $m	0.00	0.26	0.10	0.12	0.06	0.14	0.15	0.23	0.35	0.45
Income, $m
Income, $m	Revenue	1	238	198	428	309	1,176	1,416	2,459	3,810	5,343
	Gross margin, %	100.00	97.91	85.52	83.38	77.12	85.98	79.77	84.55	84.41	87.49
	EBT	(119)	(91)	(690)	(944)	(1,618)	(1,439)	(1,961)	(826)	(533)	417
	EBT margin, %	(11,136.73)	(38.20)	(348.01)	(220.35)	(523.90)	(122.30)	(138.50)	(33.59)	(13.99)	7.80
	Net income	(119)	(93)	(674)	(951)	(1,601)	(1,458)	(2,004)	(882)	(645)	287
	Depreciation	2	5	10	19	32	46	66	88	172	142
Per share, $
Per share, $	Revenue	0.03	5.71	3.58	7.13	3.70	12.68	13.73	23.55	36.19	48.99
	Earnings	(3.84)	(2.23)	(12.15)	(15.80)	(19.13)	(15.23)	(19.43)	(8.45)	(6.12)	2.63
	Cash flow	(2.88)	0.31	(9.88)	(12.49)	(15.38)	(14.00)	(14.51)	(11.09)	(1.34)	10.34
	Capex	(0.76)	(1.41)	(1.97)	(1.49)	(1.41)	(3.30)	(3.16)	(5.57)	(4.72)	(1.89)
	Free cash flow	(3.64)	(1.10)	(11.85)	(13.99)	(16.78)	(17.30)	(17.67)	(16.66)	(6.06)	8.45
	Book value	11.37	16.38	31.63	16.29	46.35	66.09	42.50	33.89	31.65	39.99
	Shares, m	31	42	55	60	83	93	103	104	105	109
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	116.40
	P/S	167.75	17.64	39.23	23.25	69.83	21.37	16.51	7.51	5.10	6.20
	P/B	2.73	6.16	4.43	10.17	5.57	4.10	5.33	5.22	5.84	7.60
	EV/Sales	106.69	14.82	31.17	21.54	56.50	16.30	13.68	6.44	4.54	5.59
	EV/FCF	(5.43)	(76.98)	(9.40)	(10.97)	(12.45)	(11.94)	(10.38)	(8.92)	(27.14)	32.41
Cash, $m
Cash, $m	Operating cash flow	(90)	13	(548)	(750)	(1,283)	(1,299)	(1,497)	(1,157)	(141)	1,128
	Capex	(23)	(59)	(109)	(90)	(118)	(306)	(325)	(581)	(497)	(206)
	Free cash flow	(113)	(46)	(657)	(840)	(1,401)	(1,605)	(1,822)	(1,739)	(638)	922
Balance, $m
Balance, $m	Working capital	339	764	1,697	862	3,885	6,014	3,739	2,393	1,777	4,405
	Total debt	17	165	198	251	533	651	538	198	166	962
	Net debt	(351)	(673)	(1,598)	(732)	(4,118)	(5,967)	(3,997)	(2,974)	(2,461)	(3,586)
	Shareholders’ equity	353	684	1,754	978	3,869	6,133	4,383	3,537	3,332	4,361
Returns, %
Returns, %	ROA	(45.63)	(12.82)	(40.88)	(49.13)	(44.28)	(20.63)	(26.87)	(14.47)	(11.00)	4.07
	ROIC	(3,627.29)	(538.37)	(282.66)	(243.08)	0.00	(541.89)	(289.43)	(134.04)	(40.76)	36.03
	ROE	(94.94)	(17.95)	(55.28)	(69.45)	(65.88)	(29.15)	(38.11)	(22.26)	(18.77)	7.46

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ARGX argenex SE	$53.2B	29.6×	32.4×	+59.46% (above 0%: growing)	+88.56% (above 0%: growing)	+537.51% (above 0%: growing)	90.60%	32.04%	Compare
RVMD Revolution Medicines, Inc.	$40.6B	— (loss-making)	— (loss-making)	−77.89% (below 0%: shrinking)	n/m	−69.98% (below 0%: shrinking)	100.00%	0.00%	Compare
ONC BeOne Medicines Ltd. - Sponsored ADR	$39.0B	62.6×	40.2×	+29.63% (above 0%: growing)	+143.68% (above 0%: growing)	+117.92% (above 0%: growing)	89.76%	19.06%
RPRX Royalty Pharma PLC	$34.3B	42.3×	21.9×	+16.50% (above 0%: growing)	−40.00% (below 0%: shrinking)	+31.57% (above 0%: growing)	100.00%	19.75%	Compare
ALNY Alnylam Pharmaceuticals, Inc.	$31.3B	39.5×	39.6×	+66.86% (above 0%: growing)	n/m	+152.82% (above 0%: growing)	76.88%	17.93%	Compare
ROIV Roivant Sciences Ltd.	$24.6B	— (loss-making)	— (loss-making)	−33.55% (below 0%: shrinking)	n/m	−29.99% (below 0%: shrinking)	80.31%	(25,380.93%)	Compare
INCY Incyte Corporation	$23.0B	13.9×	15.6×	+37.72% (above 0%: growing)	+39.71% (above 0%: growing)	+1,829.52% (above 0%: growing)	93.73%	41.69%	Compare
BNTX BioNTech SE Sponsored ADR	$22.7B	— (loss-making)	— (loss-making)	−58.53% (below 0%: shrinking)	n/m	−342.04% (below 0%: shrinking)	8.14%	(897.82%)	Compare
GMAB Genmab A/S Sponsored ADR	$22.6B	29.1×	21.0×	+24.86% (above 0%: growing)	−9.26% (below 0%: shrinking)	−7.69% (below 0%: shrinking)	92.73%	32.47%	Compare
Median of peers	$28.0B	29.6×	21.9×	+20.68%	+15.23%	+11.94%	91.67%	18.84%

All 614 Biotechnology stocks →

BeOne Medicines Ltd. - Sponsored ADR (ONC) key facts

Strength: BeOne Medicines Ltd. - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $5.3 billion, up 40.2% from fiscal 2024.
BeOne Medicines Ltd. - Sponsored ADR (ONC) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
Net income was $286.9 million, or $2.63 per share (basic), a net margin of 5.37%.
As of October 16, 2026, ONC traded at $369.06, a market capitalization of $39.0 billion.
At that price the stock trades at 62.6× trailing-twelve-month earnings and 6.7× sales.
Return on equity was 7.46% and debt-to-equity 0.17.
Its Piotroski F-score is 7 out of 9 and its Altman Z-score is 5.25 (safe zone) for fiscal 2025.